Drug Trial Radar · NCT07723482
ML-016 in Advanced Cancer With Lung and/or Liver Involvement
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Sep 25, 2026
Primary completion
Oct 2027
Study completion Oct 2030
Sponsor
- Lead sponsor
- BrYet US, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Southern Star Research
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, phase 1/2 dose-escalation and dose expansion study evaluating the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of ML-016 in participants with advanced solid tumors with lung and/or liver involvement (primary or metastatic disease).
Conditions
- Advanced Solid Tumor With Lung and/or Liver Involvement
Interventions
ML-016Drug
a pH-sensitive polymeric doxorubicin formulated in a nanoporous silicon microparticle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) during the DLT assessment periodTime frame: Days 1-21 of the first cycle of study treatment (DLT assessment period)
- Frequency and severity of adverse events (AEs) and serious AEs (SAEs)Time frame: From first dose of study drug through 30 days following the last dose of study drug
- Maximum tolerated dose (MTD) and doses recommended for expansionTime frame: Days 1-21 of the first cycle of study treatment (DLT assessment period)
- Vital Signs: Blood PressureTime frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug
- Vital Signs: Heart RateTime frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug
- Electrocardiograms (ECGs): QT IntervalTime frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug
- Echocardiograms (ECHO): LVEFTime frame: Baseline and every cycle of study drug (each cycle is 21 days) through 30 days following the last dose of study drug
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Southside Cancer Care Centre
Miranda, New South Wales, Australia · Recruiting
Illawarra Cancer Care Center, Wollongong Hospital
Wollongong, New South Wales, Australia · Not yet recruiting
Sunshine Coast Haematology and Oncology Clinic
Buderim, Queensland, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.